CalciMedica, Inc. (CALC)
NASDAQ: CALC · Real-Time Price · USD
1.950
+0.040 (2.09%)
At close: Apr 1, 2025, 4:00 PM
1.998
+0.048 (2.44%)
After-hours: Apr 1, 2025, 4:40 PM EDT
Company Description
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage.
The company’s lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma.
The company is based in La Jolla, California.
CalciMedica, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | A. Leheny |
Contact Details
Address: 505 Coast Boulevard South, Suite 307 La Jolla, California 92037 United States | |
| Phone | 858 952 5500 |
| Website | calcimedica.com |
Stock Details
| Ticker Symbol | CALC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534133 |
| CUSIP Number | 38942Q202 |
| ISIN Number | US38942Q2021 |
| Employer ID | 45-2120079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. A. Rachel Leheny Ph.D. | Chief Executive Officer and Director |
| Eric W. Roberts | Chief Business Officer and Vice Chairman of the Board |
| Dr. Kenneth A. Stauderman Ph.D. | Co-Founder and Chief Scientific Officer |
| Michael J. Dunn M.B.A., MBA | President and Chief Operating Officer |
| Dr. Anjana Rao Ph.D. | Co-Founder and Scientific Advisor |
| Dr. Patrick Hogan Ph.D. | Co-Founder and Scientific Advisor |
| Dr. Stefan Feske M.D. | Co-Founder and Scientific Advisor |
| Stephen B. Bardin | Chief Financial Officer |
| John M. Dunn J.D. | General Counsel |
| Dr. Sudarshan Hebbar M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 5, 2025 | 8-K | Current Report |
| Mar 4, 2025 | 8-K | Current Report |
| Mar 3, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 14, 2025 | 8-K | Current Report |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 20, 2024 | 424B5 | Filing |
| Dec 13, 2024 | SCHEDULE 13G | Filing |